Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Updated on: October 15,2023 187

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Updated on:October 15,2023 187

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on: October 15,2023 76

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on:October 15,2023 76

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023 258

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023 258

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on: October 15,2023 205

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on:October 15,2023 205

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023 156

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023 156

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least

Updated on: October 15,2023 191

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least

Updated on:October 15,2023 191

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on: October 15,2023 291

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on:October 15,2023 291

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023 142

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023 142

Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer?

by Edward WinsteadArtificial intelligence (AI) technologies have become part of everyday life for many people, helping with mundane tasks such as shopping online and using social media. But can AI-dri

Updated on: October 15,2023 40

Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer?

by Edward WinsteadArtificial intelligence (AI) technologies have become part of everyday life for many people, helping with mundane tasks such as shopping online and using social media. But can AI-dri

Updated on:October 15,2023 40

Study reveals promising therapeutic approach for prostate cancer bone metastasis

by TranSpreadMiR-18a-5p was overexpressed in osteoblastic lesions of PCa bone metastasis. (A–D) Bone specimens of PCa patients with bone metastasis. (A) Immunohistochemical labeling of PSA (brown repr

Updated on: October 14,2023 270

Study reveals promising therapeutic approach for prostate cancer bone metastasis

by TranSpreadMiR-18a-5p was overexpressed in osteoblastic lesions of PCa bone metastasis. (A–D) Bone specimens of PCa patients with bone metastasis. (A) Immunohistochemical labeling of PSA (brown repr

Updated on:October 14,2023 270

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on: October 14,2023 132

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on:October 14,2023 132

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on: October 14,2023 189

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on:October 14,2023 189